Form 4: Director McNeill's Sonnet BioTherapeutics Share Exchange

Sonnet BioTherapeutics Director Lori McNeill exchanged 4,394 common shares for Hyperliquid Strategies stock and CVRs following a business combination.

Summary

• Lori McNeill, a Director of Sonnet BioTherapeutics Holdings, Inc., reported a change in beneficial ownership of common stock.
• On December 2, 2025, 4,394 shares of Sonnet BioTherapeutics Common Stock were disposed of.
• This disposition occurred pursuant to a Business Combination Agreement (BCA) dated July 11, 2025.
• The BCA involved Sonnet BioTherapeutics, Rorschach I LLC, Hyperliquid Strategies Inc (HSI), TBS Merger Sub Inc, and Rorschach Merger Sub, LLC.
• As a result of the merger, Sonnet BioTherapeutics became a direct wholly-owned subsidiary of Hyperliquid Strategies Inc (HSI).
• The 4,394 shares included 4,000 restricted stock units granted on July 11, 2025, which vested at the effective time of the Company Merger, and 394 previously vested restricted stock units.
• Each restricted stock unit was exchanged for one-fifth of a share of HSI Common Stock and one Contingent Value Right (CVR).
• All reported amounts reflect a 1:22 reverse stock split effective August 31, 2023, and a 1:8 reverse stock split effective September 30, 2024.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction resulting from a pre-announced merger, indicating the successful completion of a strategic corporate event. While it's a disposition of shares in the original entity, it's an exchange for shares in the new parent company and CVRs, which is generally a neutral to slightly positive outcome for the insider in the context of a merger.

Positives

• Completion of the Business Combination Agreement, indicating a strategic transaction has finalized.
• Vesting of 4,000 restricted stock units for the reporting person, converting into new equity and CVRs.

Negatives

• The disposition of Sonnet BioTherapeutics shares means the reporting person no longer directly holds shares in the original entity, which is a consequence of the merger.

Future Outlook

The filing indicates the completion of a merger where Sonnet BioTherapeutics became a wholly-owned subsidiary of Hyperliquid Strategies Inc. This implies Sonnet's future operations will be integrated under HSI.

Industry Context

This Form 4 reports an insider transaction following a merger, which is a common event in the biotechnology or pharmaceutical industry where companies often engage in strategic combinations to consolidate assets, pipelines, or market positions. The transaction reflects the integration of Sonnet BioTherapeutics into Hyperliquid Strategies Inc.

Related Party Transactions

• The entire transaction is a result of a Business Combination Agreement, which by its nature involves related parties (the merging entities).

Stakeholder Impact

• Shareholders: Sonnet BioTherapeutics shareholders, including the reporting person, have had their shares exchanged for Hyperliquid Strategies Inc. Common Stock and Contingent Value Rights (CVRs), altering their investment vehicle and potential future returns.
• Employees: While not explicitly stated, mergers often lead to integration efforts that can impact employees of the acquired entity.
• Management: The reporting person, a Director, has transitioned her equity holdings to the new parent company.

Next Steps

• The reporting person now holds shares of Hyperliquid Strategies Inc. Common Stock and Contingent Value Rights (CVRs).
• Sonnet BioTherapeutics Holdings, Inc. is now a direct wholly-owned subsidiary of Hyperliquid Strategies Inc.

Key Dates

Keywords

Sonnet BioTherapeutics, Hyperliquid Strategies, HSI, Rorschach, Merger, Business Combination, Form 4, Insider Transaction, Director, Stock Exchange, Restricted Stock Units, CVR, Contingent Value Right, Reverse Stock Split